<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02752542</url>
  </required_header>
  <id_info>
    <org_study_id>1021193</org_study_id>
    <nct_id>NCT02752542</nct_id>
  </id_info>
  <brief_title>Personalized Indications for CBT and Antidepressants in Treating Depression</brief_title>
  <acronym>CANBIND6</acronym>
  <official_title>Personalized Indications for Cognitive Behavioural Therapy and Antidepressants in the Treatment of Major Depressive Disorder and Persistent Depressive Disorder</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nova Scotia Health Authority</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>St. Joseph's Healthcare in Hamilton, Ontario</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Queen's University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Centre for Addiction and Mental Health in Toronto, Ontario.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Nova Scotia Health Authority</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Depression currently affects close to 2 million Canadians and is the leading cause of
      disability worldwide. Pharmacological treatments (antidepressant medication) and
      psychological treatments such as cognitive-behavioural therapy are available for depression,
      but the majority of those who receive treatment have an unsatisfactory response. On average,
      the combination of pharmacological and psychological treatment achieves better results than
      either treatment alone. However, the apparently superior results of combination treatment may
      be due to the fact that different individuals preferentially respond to pharmacological or
      psychological treatment. The invesitagtors have discovered several clinical factors and
      biomarkers that predict poor response to commonly used antidepressant medication: history of
      childhood maltreatment, loss of interest and reduced activity, a biomarker of systemic
      inflammation, and a genetic marker of sensitivity to environment. Indirect evidence suggests
      that the same factors may indicate the need for psychological treatment, but their usefulness
      as differential predictors of psychological and pharmacological treatment outcomes remains to
      be established.

      The investigators will test the hypothesis that a pre-determined set of clinical variables
      (history of childhood maltreatment, loss of interest and reduced activity) and biomarkers
      (serum C-reactive protein, a marker of systemic inflammation, and short alleles of the
      serotonin transporter gene promoter polymorphism) differentially predicts response to
      antidepressants and to cognitive-behavioural psychotherapy with clinically significant
      accuracy.

      If this hypothesis is supported, the resulting predictor will allow personalized selection of
      treatment for depression, leading to improved outcomes and healthcare efficiency. Additional
      objectives include replication of additional predictors and integrative analyses aimed at
      refining the treatment choice algorithms.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Depression is among the most common and burdensome diseases worldwide and in Canada. It is
      treatable with effective pharmacological and psychological treatments, but fewer than 50% of
      individuals achieve remission with the first treatment. The unsatisfactory outcomes are at
      least partly due to a gap in evidence on which treatment benefits which individual.

      The two most commonly used treatment modalities for depression are antidepressant medication
      and psychotherapy. However, only a minority of individuals with depression achieve remission
      with each type of treatment. On average, combination of antidepressants and psychotherapy
      achieves better results than either alone, but using two treatments at the same time may be
      wasteful and unnecessary. Several lines of evidence suggest that the apparently superior
      results of combination may be due to some individuals preferentially responding to
      antidepressants and others to psychological treatment. These findings point to the
      possibility that it may be possible to improve outcomes of depression by matching
      psychological and pharmacological treatment to individuals who are most likely to benefit
      from each one. The investigators propose to close this gap using a combination of clinical
      predictors and biomarkers to optimize the choice between psychological and pharmacological
      treatment.

      The investigators have identified that a symptom profile with prominent reduction in interest
      and activity, history of maltreatment in childhood, increase in systemic inflammation, and a
      genetic variant increasing sensitivity to environment predict poor response to antidepressant
      medication. Indirect evidence suggests that the same factors may predict better response to
      cognitive-behavioural psychotherapy.

      The investigators focus on these four predictors with substantial prior evidence:

      Reduced interest and activity. A symptom dimension of interest and activity emerged as the
      strongest predictor of poor outcome of antidepressant medication treatment. This prediction
      replicated with undiminished effect size in the largest study of antidepressant treatment
      carried out to date,4 and additional independent replications confirmed its robustness.
      Cognitive behavioural therapy improves activity and interest better than antidepressant
      medication.

      Childhood maltreatment. A meta-analysis established that a history of maltreatment in
      childhood predicts non-response to antidepressants but not to psychotherapy in adults with
      depression. History of maltreatment may actually predict greater benefits from psychological
      treatment.

      Systemic inflammation. Inflammation may be a pathogenic mechanism in a proportion of
      depression cases. The invesigators found that increased C-reactive protein (CRP), a marker of
      systemic inflammation, predicted non-response to a commonly used antidepressant. Cognitive
      behavioural therapy can decrease CRP and may be the preferred treatment option for
      individuals with high levels of systemic inflammation.

      Genetic sensitivity to environment. A functional polymorphism in the serotonin transporter
      gene makes some individuals more sensitive to positive and negative effects of the
      environment. This gene encodes the molecular target of the most commonly used antidepressants
      and the polymorphism that confers sensitivity to environment also predicts non-response to
      antidepressants. A hypothesis that genetic sensitivity to environment may extend to effects
      of psychotherapy has been proposed and supported by preliminary data.

      Combination of predictors. The above predictors are at least partly independent and may
      combine to a clinically significant prediction of treatment outcomes. Reports of
      gene-environment interactions suggest that a combination of environmental and genetic factors
      may add unique value. Therefore, the investigators propose to evaluate the predictive
      validity of a pre-determined combination of the four factors in predicting differential
      outcomes of psychological and pharmacological treatment.

      Other predictors. The selection of the four predictors described above represents a balance
      between comprehensiveness and complexity, but it is not exhaustive. To maximize the potential
      for integrative analysis, the investigators will also evaluate addition potential predictors
      including anxiety, dysfunctional attitudes, and personality disorders.

      The investigators propose to test whether these four predictors in combination differentially
      predict the outcomes cognitive-behavioural psychotherapy and antidepressant medication with
      clinically significant accuracy. If this hypothesis is supported, the resulting predictor
      will allow personalized selection of treatment for depression, leading to improved outcomes
      and healthcare efficiency. Additional objectives include replication of additional predictors
      and integrative analyses aimed at refining the treatment choice algorithms.

      Depression has been reclassified into two categories: major depressive disorder (MDD), and
      persistent depressive disorder (PDD), which may be associated with distinct etiology and
      treatment response. The investigators will include individuals with MDD and PDD to provide
      results that generalize to both conditions and keep the option of exploring each separately.

      Objective: The invesitagtors' primary objective is to establish whether a predictive score
      based on a pre-determined set of clinical variables and biomarkers differentially predicts
      response to antidepressant medication and to cognitive-behavioural psychotherapy with a
      clinically significant effect size. Secondary objectives include testing each predictor
      separately, testing a gene-environment interaction between the serotonin transporter
      polymorphism and childhood maltreatment, and integrative analyses using multiple predictors
      to derive optimized prediction algorithms.

      Primary hypothesis: A score reflecting loss of interest and activity, history of childhood
      maltreatment, systemic inflammation and genetic sensitivity to environment will predict a
      better response to cognitive-behavioural therapy relative to antidepressant medication among
      adults with major depressive disorder or persistent depressive disorder. If this hypothesis
      is supported, the resulting predictor will allow personalized selection of treatment for
      depression, leading to improved outcomes and healthcare efficiency.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 31, 2016</start_date>
  <completion_date type="Anticipated">May 2020</completion_date>
  <primary_completion_date type="Anticipated">May 2019</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Total score on the Montgomery Asberg Depression Rating Scale (MADRS)</measure>
    <time_frame>2-52 weeks</time_frame>
    <description>Outcomes will be measured every 2 weeks during the 18 weeks trial and at medium-term follow ups 26 and 52 weeks after the start of treatment. The primary outcome measure will be the total score on MADRS, a valid and reliable measure, sensitive to change with treatment, with a strong internal consistency and scalability.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Global-Clinical Impression scale (GCI)</measure>
    <time_frame>2-52 weeks</time_frame>
    <description>Secondary outcome measures will include clinician-administered Global-Clinical Impression scale (GCI) administered by the treating clinician every two weeks</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quick Inventory of Depressive Symptoms (QIDS-SR)</measure>
    <time_frame>2-52 weeks</time_frame>
    <description>Secondary outcome measures will include the Quick Inventory of Depressive Symptoms (QIDS-SR) administered by the treating clinician every two weeks</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">360</enrollment>
  <condition>Major Depressive Disorder</condition>
  <condition>Persistent Depressive Disorder</condition>
  <arm_group>
    <arm_group_label>Psychotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cognitive Behavioral Therapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Pharmacotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Antidepressant medication</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Cognitive Behavioral Therapy</intervention_name>
    <description>CBT will be delivered in a one-to-one face-to-face format by trained Masters or PhD level CBT therapists who will follow a protocol adapted from existing manuals and piloted in the participating centres. Up to 20 sessions will be offered over 18 weeks, initially twice per week, then weekly and later spaced to every other week. The treatment will have core obligatory modules and flexible elements adaptable to participant's maintaining factors.</description>
    <arm_group_label>Psychotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pharmacotherapy</intervention_name>
    <description>Pharmacotherapy will be prescribed and adjusted by psychiatrists in 20-30 minute pharmacotherapy sessions once every two weeks. The manual-guided best-evidence pharmacotherapy will follow current guidelines for first, second and third line treatment.41 The primary focus will be on serotonin-reuptake inhibiting antidepressant (escitalopram 5-20mg, sertraline 50-200 mg daily) monotherapy, which may remain the only treatment for the majority of participants. Augmentation (aripiprazole 2-10mg, bupropione 150-450mg) will be offered to participants with partial response. The manual, developed as part of Canadian Biomarker Integration Network in Depression (CAN-BIND).43, also specifies admissible supportive therapeutic elements and prohibits CBT-specific techniques.</description>
    <arm_group_label>Pharmacotherapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  a diagnosis of MDD or PDD established with the Structured Clinical Interview for DSM-5
             (SCID-5), and depression being the primary problem requiring clinical attention
             (judgement of intake clinician).

          -  a minimum current severity of 14 on the 17-item Hamilton Rating Scale for Depression
             (HRSD-17)

          -  a cumulative duration of depression of at least two months (this will exclude
             short-lasting first depressive episodes that do not require treatment of this
             intensity), age 18 or more (no upper limit)

          -  capacity to provide informed consent.

        Exclusion Criteria

          -  lifetime diagnosis of bipolar disorder, schizophrenia, schizophreniform disorder,
             schizoaffective disorder, or current alcohol or drug use disorder

          -  pregnancy

          -  recent receipt of adequate trial of psychological treatment (10 or more sessions in
             the past 12 months)

          -  recently introduced antidepressant medication (new antidepressant in past 12 weeks or
             dose increase in the past 6 weeks)

          -  previous non-response to two or more of study medications

          -  acute suicide risk (MADRS suicide itemâ‰¥4)

          -  current psychotic symptoms.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rudolf Uher, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Nova Scotia Health Authority</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Rudolf Uher, MD, PhD</last_name>
    <phone>1-902-473-7209</phone>
    <email>rudolf.uher@nshealth.ca</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Beth McDougall, MSc</last_name>
    <phone>902-473-5313</phone>
    <email>beth.mcdougall@nshealth.ca</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Nova Scotia Health Authority</name>
      <address>
        <city>Halifax</city>
        <state>Nova Scotia</state>
        <zip>B3H 2E2</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rudolf Uher, MD PhD</last_name>
      <email>uher@dal.ca</email>
    </contact>
    <contact_backup>
      <last_name>Beth McDougall, MSc</last_name>
      <email>Beth.McDougall@nshealth.ca</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>April 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 25, 2016</study_first_submitted>
  <study_first_submitted_qc>April 26, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 27, 2016</study_first_posted>
  <last_update_submitted>April 25, 2017</last_update_submitted>
  <last_update_submitted_qc>April 25, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 26, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Nova Scotia Health Authority</investigator_affiliation>
    <investigator_full_name>Rudolf Uher</investigator_full_name>
    <investigator_title>Physician</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Disease</mesh_term>
    <mesh_term>Depressive Disorder</mesh_term>
    <mesh_term>Depression</mesh_term>
    <mesh_term>Depressive Disorder, Major</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antidepressive Agents</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>The investigators will not share any identifiable or anonymized data with parties other than the participating established academic institutions, which will sign a data transfer agreement (DTA) which will be created in collaboration with NSHA Research Services and subscribe to the code of ethics and confidential to rules commensurate with the TCPS2.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

